Corpus ID: 13483434

Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.

  title={Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.},
  author={J. Cavallito and C. A. Nichol and W. Brenckman and R. Deangelis and D. Stickney and W. S. Simmons and C. W. Sigel},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  volume={6 3},
With the aim of developing anticancer compounds which overcome some of the clinical limitations of the polar dihydrofolate reductase inhibitor, methotrexate, the physicochemical properties, kinetics, and metabolism of a series of lipid-soluble 2,4-diamino-5-phenylpyrimidine folate antagonists have been studied. Metoprine and etoprine, potent inhibitors of mammalian dihydrofolate reductase, were compared with pyrimethamine, a widely used antimalarial drug. The development of assay procedures in… Expand
Lipophilic Inhibitors of Dihydrofolate Reductase
The evaluation of lipophilic inhibitors of dihydrofolate reductase (DHFR) as anticancer agents is a continuing effort because of the development of clinical resistance to methotrexate (MTX) and itsExpand
Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase.
In vivo, BW 301U is active against Walker 256, L1210, P388, Sarcoma 180, and Ehrlich ascites tumors, and this compound was selected from among related pyridopyrimidines and other lipid-soluble diaminoheterocyclic compounds as having the most favorable combination of properties. Expand
Uptake, cytotoxicity and metabolism of m-azidopyrimethamine and related lipophilic antifolates in SV-K14 human keratinocytes in vivo.
The growth-inhibitory properties of a series of lipophilic diaminopyrimidine antifolates and the unexpected activity of MAP, an inferior DHFR inhibitor, suggests differences in the mechanism of action or cellular transport of the drug, although the reduction of cytotoxicity observed under folate-independent conditions indicate folate metabolism as the cytotoxic locus. Expand
Inhibitors of Dihydrofolate Reductase
Methotrexate (1b), which remains the single most important antifol anticancer agent after 30 years of clinical use, owes its activity to its stoichiometric inhibition of the enzyme dihydrofolateExpand
Dihydrofolate Reductase Inhibitors
While exploring structural variations of anilinopyrimidines with antimalarial activity, a group at Imperial Chemical Industries found that certain biguanides synthesised as ring-opened analoguesExpand
Inhibitors of Dihydrofolate Reductase as Antiprotozoal Agents
The therapeutic potential of inhibitors of dihydrofolate reductase as selectively toxic agents was first realized in early studies involving laboratory species of the genus Plasmodium. TheseExpand
The intracellular mechanism of action of metoprine (DDMP).
It is proposed that the observed biological differences between MTX and DDMP are due to the lipophilic nature of the latter giving rise to unique cell membrane transport and pharmacokinetic properties. Expand
Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
These multiple resistance factors collectively result in a prominent increase in folate accumulation, an expansion of the intracellular folylpolyglutamate pool, and abolishment of the cytotoxic activity of polyglutamatable and lipophilic antifolates. Expand
Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects
This microdose study quantitatively predicted a drug–drug interaction involving the renal clearance of metformin at ThD by pyrimethamine, which is a useful in vivo inhibitor of MATE proteins. Expand
Kinetics of metoprine, a lipid-soluble antifolate.
One partial response and one minor regression were observed in the studied patients; these two patients had the 175 mg/m2 dose, highest peak levels and AUC and highest AUCs and had neither therapeutic response nor hematologic toxicity. Expand